Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
0.61/2.84
|
|
Enterprise Value
44.36B
|
| Balance Sheet |
|
Book Value Per Share
6.32
|
| Cash Flow |
|
Cash Flow Yield
0.04
|
| Income Statement |
|
Total Revenue
16.54B
|
|
Operating Revenue Per Share
13.09
|
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2025/11/07 13:13 EST
Industry overview quotes are at least 15 minutes delayed
|
Business Description
|
|||
| Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor. |

23.99 
